InsidersTradesSigma
Mustang Bio, INC. Stock: price and directors' dealings · United States · SEC (Form 4)
Track the Mustang Bio, INC. share price and the full insider trade history of the company, a listed issuer based in United States. Shares trade on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Mustang Bio, INC. has logged 43 insider filings. Market capitalisation: €4.6m. The latest transaction was filed on 28 April 2025 (Retenue fiscale). Among the most active insiders: Litchman Manuel MD. Every trade is accessible without an account.
43
Insider Decl.
0
Thresholds
€678,947
6 ops.
Buy Volume
€17,593
2 ops.
Sell Volume
49Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 28 April 2025
Declarations43 total
27 shares@ US$1.240.0% of flowCOMMON STOCKSEC:0001104659-25-040237:0
67,806 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001415889-25-009620:0
575,191 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001104659-24-076298:0
1,396 shares@ US$0.350.1% of flowCommon StockSEC:0001104659-24-068411:0
1,248 shares@ US$12.152.0% of flowCommon StockSEC:0001104659-24-068409:0
419,092 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001104659-24-000859:0
5,000 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001104659-23-079110:0
7,246 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001104659-23-079117:0
7,246 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001104659-23-079111:0
7,246 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001104659-23-079112:0
7,246 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001104659-23-079114:0
7,246 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001104659-23-079118:0
71,664 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001104659-23-040924:0
71,664 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001104659-23-040927:0
4,094 shares@ US$0.73934.8% of flowCOMMON STOCK, PAR VALUE $0.0001SEC:0001104659-23-040932:0
Ideal exit: 13 Dec 2022 (T+270)
5,000 shares@ US$0.7390.5% of flowCOMMON STOCK, PAR VALUE $0.0001SEC:0001104659-23-040934:0
Ideal exit: 13 Dec 2022 (T+270)
71,664 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001104659-23-040923:0
71,664 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001104659-23-040929:0
2,807,008 shares0COMMON STOCK, PAR VALUE $0.0001SEC:0001104659-23-001929:0
22,500 shares0COMMON STOCKSEC:0001104659-21-150544
22,500 shares0COMMON STOCKSEC:0001104659-21-150544:0
65,000 shares@ US$2.242.74% mcap18.3% of flowCOMMON STOCKSEC:0001104659-21-135706:0
Ideal exit: 24 Jul 2022 (T+270)
65,000 shares@ US$2.242.74% mcap36.7% of flowCOMMON STOCKSEC:0001104659-21-135706
Ideal exit: 24 Jul 2022 (T+270)
4,450 shares@ US$2.280.19% mcap100.0% of flowCOMMON STOCKSEC:0001104659-21-128486
4,450 shares@ US$2.280.19% mcap50.0% of flowCOMMON STOCKSEC:0001104659-21-128486:0
25 of 43 declarations
About Mustang Bio, INC.
Mustang Bio, Inc. (MBIO) is a clinical-stage biopharmaceutical company listed on the NASDAQ in the United States. The company is focused on developing cell and gene therapies aimed at difficult-to-treat cancers, placing it squarely in the high-risk, high-upside segment of small-cap biotechnology. Mustang Bio was incorporated in Delaware on March 13, 2015, and was founded by Fortress Biotech, giving it an early strategic and financing framework through which to build its pipeline. Today, the company identifies its headquarters in Waltham, Massachusetts, a location that fits well within the US East Coast biopharma ecosystem. Its business model is centered on translational research and clinical development rather than commercial sales. Mustang Bio’s platform has historically included CAR-T programs and other precision-medicine approaches for oncology, with work spanning hematologic malignancies, solid tumors and, in some cases, rare genetic diseases. The company remains a development-stage entity and does not have an approved product on the market. For equity investors, that means the story is primarily about clinical milestones, regulatory progress, funding capacity and dilution risk rather than current operating earnings. In competitive terms, Mustang Bio operates in a crowded field dominated by larger biotech players, academic spinouts and partnership-driven platforms with deeper capital resources. Its potential advantage lies in the selective acquisition and licensing of promising technologies from leading research institutions, allowing it to focus on value creation through targeted development rather than broad commercialization. At the same time, the business remains exposed to the usual biotechnology risks: trial failures, manufacturing complexity, regulatory uncertainty and persistent capital needs. Recent corporate developments have been important for market perception. In early 2025, Mustang Bio addressed Nasdaq listing-compliance issues related to minimum bid price requirements and later announced it had regained compliance. The company also completed a 1-for-50 reverse stock split in January 2025 and raised additional capital during 2025 to support operations. In July 2025, Mustang Bio announced that the US FDA granted orphan drug designation to MB-101 for astrocytomas and glioblastoma, a notable regulatory milestone that may support the long-term investment case if clinical data continue to progress positively. Overall, MBIO remains a speculative NASDAQ-listed US biotech story whose valuation is driven by pipeline execution, financing discipline and milestone delivery.
